Title
A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers
A Clinical Pharmacology Study to Determine the Pharmacokinetic , Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of A-831 in Otherwise Healthy Male Hepatitis C Carriers With Compensated Liver Disease
Phase
Phase 1/Phase 2Lead Sponsor
Arrow TherapeuticsStudy Type
InterventionalStatus
TerminatedIndication/Condition
Chronic Hepatitis CIntervention/Treatment
azd7295 ...Study Participants
36The purposes of this study are:
to determine the safety and tolerability of multiple doses of A-831 at various doses
to determine how multiple doses of A-831 are distributed through the bloodstream
to determine if A-831 reduces the amount of Hepatitis C virus in the blood
Inclusion Criteria: Volunteers will be males of any race aged 18-60 years with a BMI between 18 and 32 kg/m2 at the time of the screening medical Volunteers who have given their written informed consent to participate in the study Volunteers who are willing and able to comply with the protocol and study procedures Volunteers who have a diagnosis of chronic hepatitis C infection and are in good health (other than history of Hepatitis C infection) Exclusion Criteria: Voulnteers with concurrent medical conditions or taking concurrent medications